Inclusion Criteria:

1. Provision of written informed consent

2. Patients who take PSA test regularly

3. Observation suitable patients for PSA change according to hormonal treatment at least
for 6months

4. Locally advanced or advanced prostate cancer patients who is suitable for hormonal
therapy

5. Prostate Cancer Patients who has been taking one treatment among 3 hormonal therapies
in below:

- Bicalutamide Monotherapy : Bicalutamide 150mg/day

- Goserelin 3.6mg/10.8mg

- MAB(Maximal Androgen Blockade) :Bicalutamide 50mg + Goserelin 3.6/10.8mg

Exclusion Criteria:

1. Prohibition use under permitted indication

2. Previous inclusion in the present study

3. Participation in a clinical study during the last 30 days